Belite Bio, Inc. ADR (BLTE) has released an update.
Belite Bio, Inc. has reported promising results from its Phase 2 trial for Tinlarebant, showing potential to slow progression in degenerative retinal diseases like Stargardt Disease and Dry AMD. The company has initiated further Phase 3 trials, DRAGON and PHOENIX, to confirm these findings. Additionally, Belite Bio successfully raised $25 million in a registered direct offering to support its ongoing clinical programs.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
